KYMR – Kymera Therapeutics, Inc.
KYMR — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.62
Margin Of Safety %
Put/Call OI Ratio
1.79
EPS Next Q Diff
-1.16
EPS Last/This Y
0.13
EPS This/Next Y
-0.81
Price
78.84
Target Price
118.27
Analyst Recom
1.04
Performance Q
-10.79
Upside
-158.8%
Beta
2.04
Ticker: KYMR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-24 | KYMR | 84.92 | 1.11 | 1.43 | 2699 |
| 2026-04-27 | KYMR | 86.76 | 1.19 | 1.20 | 2747 |
| 2026-04-28 | KYMR | 83.96 | 1.21 | 0.06 | 2848 |
| 2026-04-29 | KYMR | 81.61 | 1.31 | 1.08 | 2976 |
| 2026-04-30 | KYMR | 81.05 | 1.46 | 0.63 | 3199 |
| 2026-05-01 | KYMR | 80.67 | 1.46 | 0.57 | 3198 |
| 2026-05-04 | KYMR | 83.66 | 1.46 | 0.23 | 3203 |
| 2026-05-05 | KYMR | 82.75 | 1.44 | 0.00 | 3217 |
| 2026-05-06 | KYMR | 86.33 | 1.41 | 2.00 | 3249 |
| 2026-05-07 | KYMR | 84.63 | 1.42 | 7.88 | 3285 |
| 2026-05-08 | KYMR | 86.1 | 1.44 | 2.50 | 3322 |
| 2026-05-11 | KYMR | 84 | 1.44 | 3.33 | 3333 |
| 2026-05-12 | KYMR | 83.62 | 1.42 | 1.14 | 3306 |
| 2026-05-13 | KYMR | 85.66 | 1.43 | 0.00 | 3315 |
| 2026-05-14 | KYMR | 84.52 | 1.42 | 0.40 | 3311 |
| 2026-05-15 | KYMR | 82.26 | 1.42 | 0.89 | 3310 |
| 2026-05-18 | KYMR | 79.77 | 1.90 | 1.11 | 1549 |
| 2026-05-19 | KYMR | 78.24 | 1.81 | 1.14 | 1686 |
| 2026-05-20 | KYMR | 80.63 | 1.90 | 0.02 | 1633 |
| 2026-05-21 | KYMR | 80.56 | 1.78 | 1.00 | 1668 |
| 2026-05-22 | KYMR | 78.86 | 1.79 | 0.10 | 1671 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-24 | KYMR | 84.92 | -4.4 | -25.3 | -3.60 |
| 2026-04-27 | KYMR | 86.68 | -4.4 | -33.1 | -3.60 |
| 2026-04-28 | KYMR | 83.81 | -4.4 | -20.3 | -3.60 |
| 2026-04-30 | KYMR | 80.97 | -4.4 | -7.7 | -3.60 |
| 2026-05-01 | KYMR | 80.68 | -4.4 | -19.8 | -3.60 |
| 2026-05-04 | KYMR | 83.57 | -4.4 | - | -3.60 |
| 2026-05-05 | KYMR | 82.75 | 23.1 | - | -3.47 |
| 2026-05-06 | KYMR | 86.34 | 23.1 | - | -3.47 |
| 2026-05-07 | KYMR | 84.64 | 24.8 | - | -3.44 |
| 2026-05-08 | KYMR | 86.14 | 24.8 | - | -3.44 |
| 2026-05-11 | KYMR | 84.10 | 24.8 | - | -3.44 |
| 2026-05-12 | KYMR | 83.59 | 24.8 | - | -3.54 |
| 2026-05-13 | KYMR | 85.63 | 24.8 | - | -3.54 |
| 2026-05-14 | KYMR | 84.49 | 20.3 | - | -3.56 |
| 2026-05-15 | KYMR | 82.23 | 20.3 | - | -3.56 |
| 2026-05-18 | KYMR | 79.66 | 20.3 | - | -3.56 |
| 2026-05-19 | KYMR | 78.13 | 20.3 | - | -3.56 |
| 2026-05-20 | KYMR | 80.77 | 20.3 | - | -3.56 |
| 2026-05-21 | KYMR | 80.56 | 20.3 | - | -3.56 |
| 2026-05-22 | KYMR | 78.84 | 20.3 | - | -3.56 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-24 | KYMR | 11.52 | 8.04 | 14.79 |
| 2026-04-27 | KYMR | 11.52 | 7.74 | 13.68 |
| 2026-04-28 | KYMR | 11.52 | 7.74 | 13.68 |
| 2026-04-29 | KYMR | 11.19 | 7.74 | 13.68 |
| 2026-04-30 | KYMR | 11.52 | 7.74 | 13.68 |
| 2026-05-01 | KYMR | 11.52 | 7.74 | 13.68 |
| 2026-05-04 | KYMR | 11.52 | 7.30 | 13.68 |
| 2026-05-05 | KYMR | 11.52 | 7.30 | 13.68 |
| 2026-05-06 | KYMR | 11.42 | 7.30 | 13.68 |
| 2026-05-07 | KYMR | 11.42 | 7.30 | 13.58 |
| 2026-05-08 | KYMR | 11.42 | 7.30 | 13.58 |
| 2026-05-11 | KYMR | 11.42 | 7.58 | 13.58 |
| 2026-05-12 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-13 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-14 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-15 | KYMR | 11.39 | 7.58 | 13.67 |
| 2026-05-18 | KYMR | 11.39 | 7.34 | 13.65 |
| 2026-05-19 | KYMR | 11.50 | 7.34 | 13.65 |
| 2026-05-20 | KYMR | 11.50 | 7.34 | 13.65 |
| 2026-05-21 | KYMR | 11.50 | 7.34 | 13.62 |
| 2026-05-22 | KYMR | 11.67 | 7.34 | 13.62 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.13
Avg. EPS Est. Current Quarter
-0.76
Avg. EPS Est. Next Quarter
-1.03
Insider Transactions
11.67
Institutional Transactions
7.34
Beta
2.04
Average Sales Estimate Current Quarter
29
Average Sales Estimate Next Quarter
8
Fair Value
Quality Score
30
Growth Score
25
Sentiment Score
50
Actual DrawDown %
23.5
Max Drawdown 5-Year %
-83.5
Target Price
118.27
P/E
Forward P/E
PEG
P/S
126.05
P/B
4.21
P/Free Cash Flow
EPS
-3.57
Average EPS Est. Cur. Y
-3.56
EPS Next Y. (Est.)
-4.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-611.96
Relative Volume
0.88
Return on Equity vs Sector %
-47.5
Return on Equity vs Industry %
-31.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
◆
KYMR
Healthcare
$78.89
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
40.8
Range 1M
12.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
5.1%
EPS NY
-22.8%
52W%
67.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+49.9% upside
Upside
+49.9%
Quality
30
Kymera Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 253
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR
Latest News
—
Caricamento notizie per KYMR…
stock quote shares KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading